ValuEngine upgraded shares of Innoviva, Inc. (NASDAQ:INVA) from a hold rating to a buy rating in a research report released on Monday morning.

Other analysts also recently issued research reports about the company. Zacks Investment Research downgraded Innoviva from a strong-buy rating to a hold rating in a research note on Wednesday, August 16th. Cowen and Company set a $16.00 target price on Innoviva and gave the company a buy rating in a research report on Friday, July 28th. Robert W. Baird reiterated a neutral rating and set a $13.00 target price (up from $11.00) on shares of Innoviva in a research report on Thursday, July 27th. Finally, Stifel Nicolaus reissued a hold rating and issued a $15.00 target price on shares of Innoviva in a report on Friday, July 28th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $15.00.

Shares of Innoviva (NASDAQ INVA) traded up 0.21% during trading on Monday, hitting $14.52. The company had a trading volume of 84,900 shares. Innoviva has a 52 week low of $8.67 and a 52 week high of $14.87. The firm’s 50 day moving average is $13.48 and its 200-day moving average is $12.92. The stock has a market capitalization of $1.59 billion, a P/E ratio of 18.26 and a beta of 2.60.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. Innoviva had a negative return on equity of 27.37% and a net margin of 52.56%. The company had revenue of $58.60 million during the quarter, compared to analyst estimates of $50.53 million. During the same period in the prior year, the company earned $0.13 earnings per share. The firm’s revenue was up 80.3% on a year-over-year basis. Equities research analysts anticipate that Innoviva will post $1.16 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/innoviva-inc-inva-upgraded-to-buy-by-valuengine/1605280.html.

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. grew its position in Innoviva by 68,215.3% in the first quarter. BlackRock Inc. now owns 12,000,259 shares of the biotechnology company’s stock worth $165,964,000 after acquiring an additional 11,982,693 shares in the last quarter. Comerica Bank increased its stake in Innoviva by 4.5% during the first quarter. Comerica Bank now owns 85,950 shares of the biotechnology company’s stock worth $1,082,000 after acquiring an additional 3,673 shares during the last quarter. Morgan Stanley increased its stake in Innoviva by 92.2% during the first quarter. Morgan Stanley now owns 564,427 shares of the biotechnology company’s stock worth $7,807,000 after acquiring an additional 270,824 shares during the last quarter. KCG Holdings Inc. increased its stake in Innoviva by 63.9% during the first quarter. KCG Holdings Inc. now owns 30,265 shares of the biotechnology company’s stock worth $419,000 after acquiring an additional 11,802 shares during the last quarter. Finally, Teachers Advisors LLC raised its position in Innoviva by 3.4% during the first quarter. Teachers Advisors LLC now owns 135,848 shares of the biotechnology company’s stock valued at $1,879,000 after purchasing an additional 4,452 shares during the period. 69.06% of the stock is owned by hedge funds and other institutional investors.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.